Hagen Kennecke, MD, MHA, FRCPC: Cabozantinib as a Treatment Option Following Progression in NET

Dr. Hagen Kennecke discusses the use of cabozantinib in the treatment of patients with NET who progressed on prior therapies.

MORE EXPERT PERSPECTIVES IN NET:

Hagen Kennecke, MD, MHA, FRCPC: Benefit of Cabozantinib in Patients with Advanced Neuroendocrine Tumors

Hagen Kennecke, a medical oncologist and professor of medicine at Oregon Health Sciences University, discusses the efficacy of cabozantinib in patients with advanced neuroendocrine tumors, specifically in relation to progression-free survival.

Neena Vijayvergia, MD: Importance of Patient Education for Treating Neuroendocrine Tumors

Learn why patient education and strong communication with your care team are important when treating neuroendocrine tumors.
Linkedin Instagram Youtube Spotify Facebook X-twitter Threads

©2026 Oncology Matrix. All Rights Reserved.